Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 20Carcinoma, Renal Cell 12Colorectal Neoplasms 10Kidney Neoplasms 8Ovarian Neoplasms 6Neoplasms 5Carcinoma, Transitional Cell 5Urethral Neoplasms 4Stomach Neoplasms 4Prostatic Neoplasms 4Pancreatic Neoplasms 4Neoplasm Metastasis 4Lung Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 4Triple Negative Breast Neoplasms 3Melanoma 3Head and Neck Neoplasms 3Esophageal Neoplasms 3Colonic Neoplasms 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 2Multiple Myeloma 2Hematologic Neoplasms 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Cholangiocarcinoma 2Carcinoma, Hepatocellular 2Urothelial Carcinoma of the Bladder 1

Interventions

Vinblastine 1Transurethral Resection of Bladder 1Radiotherapy, Intensity-Modulated 1Proton Therapy 1Mitomycin 1Methotrexate 1Fluorouracil 1Doxorubicin 1Cisplatin 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urothelial Carcinoma of the Bladder × Fluorouracil × Genitourinary × Clear all
NCT02710734 2026-05-22

Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)

Fox Chase Cancer Center

Phase 2 Completed
78 enrolled
Genitourinary

Urothelial Carcinoma of the Bladder

Data powered by HemOnc (CC BY 4.0) Colophon âš¡